For example, c-myelocytomatosis (MYC),an oncoprotein TF, uses the druggable WD repeat-containingprotein 5 (WDR5) as a cofactor.5−8 MYC is overexpressed in 70% of human cancers and controls genesthat influence cell development and apoptosis.9−13 Experimental evidence indicated that MYC interactswith WDR5,7,14 utilizing one of its intrinsically disorderedregions and the WDR5 binding motif (WBM) site.15 For simplicity, this binding region of MYC is called MYCWBM (Figure 1a,b and Table S1). This evidence concerns the gene WDR5 and cancer.